... WhatsApp

How Nivolumab Immunotherapy Helps Older Patients with Advanced Kidney Cancer

You are here >> Home > Latest Updates > Kidney Cancer > How Nivolumab…

Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metasta DOI- 10.1016j.jgo.2025.102336

Kidney cancer is more common in older adults. But most studies on new treatments focus on younger patients. That’s why this study is important. It shows that immunotherapy works just as well in older patients with advanced kidney cancer.

Researchers looked at nearly 900 people with metastatic kidney cancer. Some were under 70. Others were 70 or older. Everyone received immunotherapy with a drug called nivolumab, either alone or with another drug, ipilimumab.

The results were clear: survival was similar for both groups. Older patients lived just as long and had the same time before the cancer worsened. This means age should not be a reason to avoid immunotherapy.

The study also looked at tools doctors use to predict outcomes. A newer tool, called the Meet-URO score, gave more accurate predictions than the older system. This can help doctors make better decisions about treatment plans.

If you’re over 70 and facing advanced kidney cancer, this research offers good news. Immunotherapy is a strong option, and there are better ways to guide your treatment now.

Rate this post
Robotic Cancer Surgery

Exclusive Health Tips and Updates

Best robotic cancer surgery in Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.